A double-blind, placebo-controlled MAD trial of RAP 219 in healthy volunteers
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs RAP 219 (Primary)
- Indications Bipolar disorders; Neuropathic pain; Partial epilepsies
- Focus Adverse reactions; Pharmacokinetics
- Acronyms MAD-2
- 15 Jan 2025 New trial record
- 09 Jan 2025 According to Rapport Therapeutics media release, clinical conduct of the trial is complete and the clinical study report for the trial is in progress.
- 09 Jan 2025 Status changed from recruiting to completed.